Evidence map›Paper›PMID 40158188›Full record

ArticleAIDS research and therapy2025

Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries-an extension study of eight countries.

Thomas C Scheier, Tafese Beyene Tufa, Torsten Feldt, Yasmine Hardy, Albert Minga, Raoul Moh, Albertino Damasceno, Lucia Chambal, Francine Ntoumi, Carine Kades and 10 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Thomas C ScheierPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Tafese Beyene TufaAsella Referral and Teaching Hospital, College of Health Sciences, Arsi University, P.O. Box 04, Asella, Ethiopia.
Torsten FeldtHirsch Institute of Tropical Medicine (HITM), Heinrich-Heine University, P.O. Box 04, Asella, Ethiopia.
Yasmine HardyDirectorate of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Albert MingaCentre Médical de Suivi des Donneurs de Sang (CMSDS-CNTSCI), Abidjan, Côte d'Ivoire.
Raoul MohProgramme PAC-CI, Site ANRS de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Albertino DamascenoFaculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Lucia ChambalFaculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Francine NtoumiFondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo.
Carine KadesFondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo.
Leopold BitunguhariDepartment of Internal Medicine, University Teaching Hospital of Kigali, Kigali, Rwanda.
Osee R SebatunziDepartment of Internal Medicine, University Teaching Hospital of Kigali, Kigali, Rwanda.
Marco MissangaNIMR-Mbeya Medical Research Center, Mbeya, Tanzania.
Katanekwa NjekwaCenter for Infectious Disease Research in Zambia (CIDRZ), P.O. Box 34681, 10101, Lusaka, Zambia.
Monde MuyoyetaCenter for Infectious Disease Research in Zambia (CIDRZ), P.O. Box 34681, 10101, Lusaka, Zambia.
Sumathy RangarajanPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Graeme MeintjesWellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, Republic of South Africa.
Dominik MertzPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
John W EikelboomPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Sean WassermanWellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, Republic of South Africa. swasserm@sgul.ac.uk.

Funding

PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisU01AI170426 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SERENA Patricia KOENIG, Sean Wasserman · 2022 to 2026
$5.9M
Bill and Melinda Gates Foundation INV-052110NIAID NIH HHS U01 AI170426NIH HHS U01AI170426Wellcome TrustWellcome Trust 214321/Z/18/Z and 203135/Z/16/Z
6 · The paper itself

Abstract

introductionThe World Health Organization (WHO) has published guidelines for the management of patients with advanced HIV disease (AHD) but mortality remains high. Adoption of WHO recommendations by national guidelines is poorly documented. We aimed to extend our prior review of six national management guidelines by including additional countries from sub-Saharan Africa.

methodsWe identified guidelines of eight additional countries participating in a multicountry trial of azithromycin prophylaxis for AHD. Data was extracted in five domains including definition of AHD (1 item), screening (6 items), prophylaxis (6 items), supportive care (1 items), and HIV treatment (4 items) and scored agreement of each national guideline with the WHO guidelines.

resultsSix of the eight national guidelines had a designated section for AHD. Compared with the WHO guideline, the agreement score for national guidelines was between 7 and 17 out of 18, whereby disagreement is mainly driven by missing information. None of the national guidelines had more than three items not in agreement with the WHO guidelines, and the maximum number of items not addressed by any one guideline was eight. Main areas of disagreement were the targeted population for start of ART in presence of tuberculosis meningitis (1/8 in agreement) and urine lipoarabinomannan screening (2/8 in agreement). The targeted population group for cotrimoxazole prophylaxis and its discontinuation was in line with the WHO recommendations in 3/8 national guidelines. Except one guideline, all documents showed similar overall agreement, irrespectively of publication date.

conclusionNational guidelines for the management of people with AHD are broadly in agreement with WHO guidelines. Main areas of disagreement are recommendations regarding urine lipoarabinomannan screening, cotrimoxazole prophylaxis and start of antiretroviral therapy in presence of tuberculosis.

Indexed as

Anti-HIV AgentsHIV InfectionsPractice Guidelines as TopicStandard of CareAfrica South of the SaharaAzithromycinHumansTrimethoprim, Sulfamethoxazole Drug CombinationWorld Health OrganizationAnti-HIV AgentsAzithromycinTrimethoprim, Sulfamethoxazole Drug CombinationAdvanced HIV diseaseAntiretroviral therapyGuidelinesSub-Saharan Africa

Identifiers

PMID40158188
PMCPMC11955106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.